13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults
作者： Greg L. Plosker
DOI: 10.1007/S40265-015-0449-Z
关键词: Pneumococcal polysaccharide vaccine 、 Medicine 、 Immunization 、 Immunogenicity 、 Serotype 、 Streptococcus pneumoniae 、 Pneumococcal infections 、 Pneumococcal conjugate vaccine 、 Immunology 、 Pneumonia 、 Internal medicine
摘要: The 13-valent pneumococcal conjugate vaccine (Prevenar 13(®), Prevnar 13(®)) [PCV13] consists of 13 serotype-specific polysaccharides Streptococcus pneumoniae (pneumococcus), each covalently conjugated to a non-toxic immunogenic carrier protein. PCV13 has well established immunogenicity and tolerability profile in adults, particularly those ≥50 years age. Results CAPiTA, randomized, double-blind, placebo-controlled trial >84,000 older adults aged ≥65 years, showed that was effective preventing vaccine-type community-acquired pneumonia (CAP), nonbacteraemic (noninvasive) CAP invasive disease (IPD). These findings, along with changes serotype distribution epidemiology disease, prompted the US Advisory Committee on Immunization Practices (ACIP) recommend series 23-valent polysaccharide (PPVS23) for all years. also role (pneumonia IPD) younger immunocompromising conditions potentially other underlying medical increase risk disease.
springer.com
sci-hub.se 参考文章(61)
John D. Grabenstein, Megan A. O’Brien, Jieling Chen, Cost-effectiveness of adult pneumococcal vaccination: responding to: Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012;30(August (36)):5437-44. Vaccine. ,vol. 31, pp. 1549- ,(2013) , 10.1016/J.VACCINE.2012.10.110
Julien Mazieres, Paul Leophonte, Treatment and prevention of pneumococcal pneumonia La Revue du praticien. ,vol. 53, pp. 1451- 1457 ,(2003)
Mark Sanford, Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) Drugs. ,vol. 72, pp. 1243- 1255 ,(2012) , 10.2165/11209330-000000000-00000
Giorgio Liguori, Giorgio Liguori, Antonino Parlato, Antonino Parlato, Alessandro Sanduzzi Zamparelli, Alessandro Sanduzzi Zamparelli, Patrizia Belfiore, Patrizia Belfiore, Francesca Gallé, Francesca Gallé, Valeria Di Onofrio, Valeria Di Onofrio, Carla Riganti, Carla Riganti, Bruno Zamparelli, Bruno Zamparelli, Società Italiana di Health Horizon Scanning (SIHHS), Società Italiana di Health Horizon Scanning (SIHHS), Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation. Human Vaccines & Immunotherapeutics. ,vol. 10, pp. 492- 497 ,(2014) , 10.4161/HV.26888
Matthew R Moore, Ruth Link-Gelles, William Schaffner, Ruth Lynfield, Catherine Lexau, Nancy M Bennett, Susan Petit, Shelley M Zansky, Lee H Harrison, Arthur Reingold, Lisa Miller, Karen Scherzinger, Ann Thomas, Monica M Farley, Elizabeth R Zell, Thomas H Taylor, Tracy Pondo, Loren Rodgers, Lesley McGee, Bernard Beall, James H Jorgensen, Cynthia G Whitney, Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: Analysis of multisite, population-based surveillance Lancet Infectious Diseases. ,vol. 15, pp. 301- 309 ,(2015) , 10.1016/S1473-3099(14)71081-3
Silvio D. Brugger, Kathrin Mühlemann, Markus Hilty, Jurka Meichtry, Rita Born, Marianne Küffer, Marcel Zwahlen, Werner C. Albrich, Serotype epidemiology of invasive pneumococcal disease in Swiss adults: A nationwide population-based study Vaccine. ,vol. 32, pp. 5185- 5191 ,(2014) , 10.1016/J.VACCINE.2014.07.060
Kevin L. Russell, Carolyn I. Baker, Christian Hansen, Gregory A. Poland, Margaret A.K. Ryan, Mary M. Merrill, Gregory C. Gray, Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: a randomized, double-blind, placebo-controlled trial. Vaccine. ,vol. 33, pp. 1182- 1187 ,(2015) , 10.1016/J.VACCINE.2014.12.058
P. P. Gounder, M. G. Bruce, D. J. T. Bruden, R. J. Singleton, K. Rudolph, D. A. Hurlburt, T. W. Hennessy, J. Wenger, Effect of the 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization by Streptococcus pneumoniae—Alaska, 2008–2012 The Journal of Infectious Diseases. ,vol. 209, pp. 1251- 1258 ,(2014) , 10.1093/INFDIS/JIT642
Yiling Jiang, Aline Gauthier, Lieven Annemans, Mark van der Linden, Laurence Nicolas-Spony, Xavier Bresse, A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany. Expert Review of Pharmacoeconomics & Outcomes Research. ,vol. 12, pp. 631- 643 ,(2012) , 10.1586/ERP.12.55
Pekka O. Honkanen, Timo Keistinen, Liisa Miettinen, Elja Herva, Ulla Sankilampi, Esa Läärä, Maija Leinonen, Sirkka-Liisa Kivelä, P. Helena Mäkelä, Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older Vaccine. ,vol. 17, pp. 2493- 2500 ,(1999) , 10.1016/S0264-410X(99)00069-9